Live Breaking News & Updates on Janssen Cilag International

Stay updated with breaking news from Janssen cilag international. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Region Flamande , Soult Ukpyolsi , South Korea , United States , Republic Of Korea , Byoung Chul Cho , Henar Hevia , Craig Tendler , American Lung Association , Slate Development , Janssen Cilag International , American Society Of Clinical Oncology , European Medicines Agency Seeking Approval , Janssen Cilag International Nv Inc , Committee For Medicinal Products Human Use , National Cancer Institute , European Society For Medical Oncology , Exchange Commission , None Of Janssen Cilag International , European Medicines Agency , Yonsei University College Of Medicine , Global Medical Affairs , American Society For Clinical Oncology Annual Meeting , European Commission , Clinical Oncology , Annual Meeting ,

Johnson & Johnson Submits Application To The European Medicines Agency Seeking Approval Of Subcutaneous Formulation Of RYBREVANT®▼ (Amivantamab) For T...

Johnson & Johnson Submits Application To The European Medicines Agency Seeking Approval Of Subcutaneous Formulation Of RYBREVANT®▼ (Amivantamab) For T...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United States , Region Flamande , Natasha Leighl , Henar Hevia , Natashab Leighl , American Lung Association , European Medicines Agency Seeking Approval , European Medicines Agency , American Society Of Clinical Oncology Annual Meeting , Princess Margaret Cancer Centre , None Of Janssen Cilag International , Janssen Cilag International , Exchange Commission , American Society Of Clinical Oncology , European Commission , American Society , Clinical Oncology , Annual Meeting , Senior Director , Area Lead , Johnson Innovative Medicine , European Economic Area , Product Characteristics , Innovative Medicine , Private Securities Litigation Reform Act , Annual Report ,

Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn's disease treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing Authorization Application for TREMFYA® (guselkumab) to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease. ....

David Lee , European Medicines Agency , Drug Administration , European Union , Janssen Cilag International , Marketing Authorization Application , Ludovic De Beaucoudrey , Senior Director , Therapeutic Area Lead , Janssen Cilag Limited , Global Therapeutic Area Head Immunology , Johnson Innovative , Disease Week Annual Meeting , United European Gastroenterology Week , Biologics License Application , Crohns Disease , Ulcerative Colitis ,

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor. ....

Comunidad Autonoma De Cataluna , Region Flamande , San Antonio , United States , Europ Urol , Janssen Pharmaceutica , Tanakam Sonpavde , Clin Pharmacol , Sabine Brookman , Henar Hevia , Indianj Urol , Astex Therapeutics , Drug Administration , European Medicines Agency , None Of Janssen Cilag International , European Society For Medical Oncology , Late Development Oncology , Astex Pharmaceuticals , Astex Announces New Drug Discovery Alliance , American Urological Association Annual Meeting , Exchange Commission , European Medicines Agency Seeking Approval Of Erdafitinib , Janssen Cilag International Nv Inc , American Cancer Society , Janssen Cilag International , Urological Association ,

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate. ....

United States , Region Flamande , San Antonio , Henar Hevia , Luca Dezzani , Exchange Commission , Janssen Research Development , American Urological Association Annual Meeting , Steering Committee , Janssen Cilag International , None Of Janssen Cilag International , European Medicines Agency , Janssen Cilag International Nv Inc , Oral Presentation Session , Urological Association Annual Meeting , Steering Committee Chair , Chief Medical Officer , Surgical Oncology , Vice President , Medical Affairs , Solid Tumour , Johnson Innovative , Senior Director , Area Lead , Innovative Medicine , Cilag International ,